With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.2213-63-0,2,3-Dichloroquinoxaline,as a common compound, the synthetic route is as follows.
Reference Example 20 To a suspension of 2,3-dichloroquinoxaline (300 mg, 1.51 mmol) in methanol (15 mL) and N,N-dimethylformamide (1.0 mL) was added sodium methoxide (28% in methanol, 309 mg, 1.66 mmol) dropwise at 0 0C. After being stirred for 2 hour at room temperature, the reaction mixture was concentrated in vacuo. The residue was diluted with chloroform and water. The organic layer was separated with phase separator and concentrated in vacuo. The residue was purified by silica gel column chromatography (hexane to hexane: ethyl acetate = 19: 1) to give 2-chloro-3-methoxyquinoxaline (the compound of Reference Example 20 listed in Table of Reference Example as described hereinafter) as a colorless powder (251 mg,%)., 2213-63-0
The synthetic route of 2213-63-0 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; MITSUBISHI TANABE PHARMA CORPORATION; MORIMOTO, Hiroshi; SAKAMOTO, Toshiaki; HIMIYAMA, Toshiyuki; KAWANISHI, Eiji; MATSUMURA, Takehiko; WO2010/30027; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider